Investors
Corporate Profile
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.
Click here to view the Ocugen 2022 R&D Day event
Ocugen News
November 29, 2023 Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
November 10, 2023 Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
November 9, 2023 Ocugen Provides Business Update with Third Quarter 2023 Financial Results
Corporate Presentation
Events
Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference December 4, 2023 at 2:00 PM EST
Ocugen, Inc. Third Quarter 2023 Financial Results and Recent Business Highlights November 9, 2023 at 8:30 AM EST